• Audrey-Elodie Mercier, Emmanuel Ribeiro, Jean-François Korobelnik, Marie-Noëlle Delyfer, and Marie-Bénédicte Rougier.
• a Department of Ophthalmology , University Hospital, Place Amélie Raba Léon , Bordeaux , France.
• Ocul. Immunol. Inflamm. 2018 Jan 1; 26 (3): 477-484.

PurposeTo assess the efficacy of anti-TNF alpha (TNF-α) therapy in patients with non-infectious uveitis.MethodsThis was a monocentric observational study of 21 patients with non-infectious uveitis treated with anti-TNF-alpha. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular thickness and visual acuity, changes in other treatments, and adverse effects.ResultsThe etiologies of uveitis were Behçet disease (33.3%), birdshot (14.3%), sarcoidosis (9.5%), and idiopathic uveitis (42.9%). Ocular inflammation was controlled at 3 months for 80.9% of patients, at 6 months for 94.7%, at 12 months for 83.3%, and at >12 months for 86.7%. Central macular thickness improved from 452 µm at baseline to 307.5 µm at 12 months (p = 0.002). Visual acuity also improved from 0.51(logMAR) before treatment to 0.24 at 12 months. The mean daily dose of prednisone decreased from 19.7 mg before treatment to 5.2 mg at 12 months (p < 0.001). A total of 9.5% of patients experienced serious side-effects.ConclusionsOur study confirms the efficacy of anti-TNF for the control of short-term and long-term ocular inflammation, with high rates of complete clinical remission.

25 keywords...

hide…